Yare a ɛma obi yɛ hahaaha yi ano aduru nni hɔ, nanso akwan pii wɔ hɔ a wɔfa so sa yare no de te ne ho yare na ɛmma ne nkɔanim nyɛ den.
Saa ayaresa yi bi ne:
1. Nnuru: Nnuru pii wɔ hɔ a ebetumi aboa ma wɔadi Alzheimer yare no ho nsɛnkyerɛnne no so.
Eyinom bi ne cholinesterase inhibitors, te sɛ donepezil, rivastigmine, ne galantamine, a ebetumi aboa ma adwene ne nkae adwuma atu mpɔn.
Memantine yɛ aduru foforo a ebetumi aboa ma obi ahu ade yiye na wanya suban pa.
2. Asetra kwan a wɔbɛsesa: Apɔwmuteɛteɛ a wɔbɛyɛ daa, aduan pa a wobedi, ne nnipa a wɔne wɔn bɛbɔ fekuw betumi aboa wɔn a wɔwɔ Alzheimer yare no ma wɔanya akwahosan pa.
3. Adwene ne nneyɛe mu ayaresa: Adwene ne nneyɛe mu ayaresa te sɛ adwene mu ahoɔden a wɔde hyɛ obi so no betumi aboa ma adwene ne adwene a ɛkae ade ayɛ adwuma yiye wɔ wɔn a wɔwɔ Alzheimer yare no mu.
Nneyɛe mu ayaresa te sɛ adwene mu nneyɛe mu ayaresa betumi aboa ma yɛadi nneyɛe mu nsɛnkyerɛnne so na ama yɛn asetra atu mpɔn.
4. Ayaresa a wɔde boa: Ayaresa a wɔde boa te sɛ adwuma mu ayaresa, kasa mu ayaresa, ne apɔw mu ayaresa betumi aboa wɔn a wɔwɔ Alzheimer yare no ma wɔatumi ayɛ wɔn ho wɔn ho adwuma bere tenten sɛnea wobetumi.
5. Ayaresabea mu nhwehwɛmu: Sɛ obi nya ayaresa foforo ho nimdeɛ a, ebetumi ama wanya ayaresa a edi mu na aboa ma wɔanya aduru foforo a wɔde bɛsa Alzheimer yare no.
Ɛho hia sɛ wo ne oduruyɛfo a ɔhwɛ wo no bom yɛ nhyehyɛe a wode bɛhwɛ Alzheimer yare no, efisɛ ahiade ne nsɛnkyerɛnne a onipa biara wɔ no betumi asesa.
Afei nso, ɛho hia sɛ wɔboa ɔyarefo no ne wɔn a wɔhwɛ no no ma wonya nkate fam awerɛkyekye na wɔhwɛ wɔn.
Kumar A, Singh A, Aggarwal A: Therapeutic potentials of herbal drugs for Alzheimer’s disease—An overview. Indian J Exp Biol. 2017, 55 (2): 63-73.
Sutor B, Rasmussen KG: Electroconvulsive therapy for agitation in Alzheimer disease: a case series. J ECT. 2008, 24 (3): 239-41.
Boada M, Ramos-Fernández E, Guivernau B, Muñoz FJ, Costa M, Ortiz AM, Jorquera JI, Núñez L, Torres M, Páez A: Treatment of Alzheimer disease using combination therapy with plasma exchange and haemapheresis with albumin and intravenous immunoglobulin: Rationale and treatment approach of the AMBAR (Alzheimer Management By Albumin Replacement) study. Neurologia. 2016, 31 (7): 473-81.
Golde TE: The Abeta hypothesis: leading us to rationally-designed therapeutic strategies for the treatment or prevention of Alzheimer disease. Brain Pathol. 2005, 15 (1): 84-7.
Giacobini E: Therapy of Alzheimer disease: symptomatic or neuroprotective? J Neural Transm Suppl. 1994, 43 (): 211-7.
Haussmann R, Donix M: [Memantine as add-on medication to acetylcholinesterase inhibitor therapy for Alzheimer dementia]. Nervenarzt. 2017, 88 (1): 40-45.
['Nsɛm a Ɛnsɛ sɛ Wɔka:']
['Wɔayɛ wɛbsaet yi sɛ wɔmfa nkyerɛkyerɛ na wɔmfa nkyerɛkyerɛ afoforo, na ɛnyɛ sɛ wɔde rema aduruyɛ ho afotu anaa wɔde rema adwuma.']
['Ɛnsɛ sɛ wɔde nsɛm a wɔde ama no di dwuma de hwehwɛ yare bi ho yare anaa wɔde sa yare, na ɛsɛ sɛ wɔn a wɔrehwehwɛ ayaresa ho afotu no kohu oduruyɛfo a ɔwɔ tumi krataa.']
['Yɛsrɛ wo hyɛ no nsow sɛ, sɛnea wɔhwɛ nsɛmmisa no so no, sɛ ɛba sɛ wɔrekyerɛw nnipa dodow a wɔanya yare bi ho asɛm a, ɛntaa nsi yiye.']
['Hwehwɛ afotu fi wo duruyɛfo anaa ɔyaresafo foforo a ɔfata hɔ bere biara wɔ yare bi ho. Nnya adwene sɛ wo nsa bɛka oduruyɛfo afotu anaasɛ wubetwa so esiane biribi a woakenkan wɔ wɛbsaet yi so nti. Sɛ wususuw sɛ ebia wo ho behia wo wɔ ayaresa mu a, frɛ 911 anaa kɔ ayaresabea a ɛbɛn wo paa ntɛm ara.']
['Nsɛm a wɔmmɔ ho ban:']
['Digital Millennium Copyright Act a wɔhyɛe wɔ afe 1998 mu, 17 U.S.C. § 512 (DMCA) no ma wɔn a wɔwɔ hokwan sɛ wɔyɛ wɔn nneɛma no kwan sɛ wɔyɛ nea wɔpɛ biara.']
["Sɛ wugye di sɛ nsɛm anaa nneɛma a ɛwɔ yɛn wɛbsaet anaa yɛn dwumadibea no mu bi to wo mmara a wode bɔɔ nneɛma ho ban no a, wo (anaa w'ananmusifo) betumi de krataa akɔma yɛn de aka sɛ yɛnyi nsɛm anaa nneɛma no, anaa yɛmmɔ kwan mma wonnya bi."]
["Ɛsɛ sɛ wɔde krataa ne email na ɛbɔ amanneɛ (hwɛ 'Contact' afã hɔ na wubehu email address)."]
['DMCA hwehwɛ sɛ wo amanneɛbɔ a ɛfa nea wɔkyerɛ sɛ ɛyɛ mmara a wobu so ho no de nsɛm a edidi so yi ka ho: (1) adwuma a mmara bɔ ho ban a wɔkyerɛ sɛ wɔadi so no ho asɛm; (2) nsɛm a wɔkyerɛ sɛ wɔadi so no ho asɛm ne nsɛm a ɛbɛboa yɛn ma yɛahu baabi a ɛwɔ; (3) wo ho nsɛm a yɛde bedi nkitaho, a wo address, telefon nɔma ne email address ka ho; (4) wo nsɛm a ɛkyerɛ sɛ wugye di sɛ nea wɔabɔ ho sobo no nyɛ nea mmara ma ho kwan; ']
['(5) wo nsahyɛ a ɛkyerɛ sɛ nsɛm a ɛwɔ amanneɛbɔ no mu yɛ nokware, na wowɔ tumi sɛ wode nea wɔkyerɛ sɛ woadi ho dwuma no bedi dwuma; ']
['ne (6) nea ɔwɔ tumi sɛ ɔyɛ biribi ma obi a ɔwɔ tumi sɛ ɔyɛ biribi ma no no nsaano nkyerɛwee.']
['Sɛ woamfa nsɛm a yɛaka yi nyinaa anka ho a, ebetumi ama wo ka no akyɛ.']
['Nkitahodi']
['Yɛsrɛ wo, fa nsɛmmisa anaa nyansahyɛ biara a wowɔ brɛ yɛn wɔ e-mail so.']
How to treat alzheimer?
There is no cure for Alzheimer's disease, but there are several treatment options available to help manage the symptoms and slow the progression of the disease.
Some of these treatments include:
1. Medications: There are several medications available that can help manage the symptoms of Alzheimer's disease.
These include cholinesterase inhibitors, such as donepezil, rivastigmine, and galantamine, which can help improve cognitive function and memory.
Memantine is another medication that can help with cognitive function and behavioral symptoms.
2. Lifestyle changes: Engaging in regular physical exercise, eating a healthy diet, and maintaining social connections can help improve overall health and well-being for people with Alzheimer's disease.
3. Cognitive and behavioral therapies: Cognitive therapies, such as cognitive stimulation therapy, can help improve cognitive function and memory in people with Alzheimer's disease.
Behavioral therapies, such as cognitive behavioral therapy, can help manage behavioral symptoms and improve quality of life.
4. Supportive care: Supportive care, such as occupational therapy, speech therapy, and physical therapy, can help people with Alzheimer's disease maintain their independence and function as long as possible.
5. Clinical trials: Participating in clinical trials for new treatments and therapies can provide access to cutting-edge treatments and help contribute to the development of new treatments for Alzheimer's disease.
It is important to work closely with a healthcare provider to develop an individualized treatment plan for Alzheimer's disease, as the needs and symptoms of each person can vary.
Additionally, it is essential to provide emotional support and care for both the person with Alzheimer's disease and their caregivers.
Disclaimer: medical
This web site is provided for educational and informational purposes only and does not constitute providing medical advice or professional services.
The information provided should not be used for diagnosing or treating a health problem or disease, and those seeking personal medical advice should consult with a licensed physician.
Please note the neural net that generates answers to the questions, is specially inaccurate when it comes to numeric content. For example, the number of people diagnosed with a specific disease.
Always seek the advice of your doctor or other qualified health provider regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website. If you think you may have a medical emergency, call 911 or go to the nearest emergency room immediately. No physician-patient relationship is created by this web site or its use. Neither BioMedLib nor its employees, nor any contributor to this web site, makes any representations, express or implied, with respect to the information provided herein or to its use.
Disclaimer: copyright
The Digital Millennium Copyright Act of 1998, 17 U.S.C. § 512 (the “DMCA”) provides recourse for copyright owners who believe that material appearing on the Internet infringes their rights under U.S. copyright law. If you believe in good faith that any content or material made available in connection with our website or services infringes your copyright, you (or your agent) may send us a notice requesting that the content or material be removed, or access to it blocked. Notices must be sent in writing by email (see 'Contact' section for email address) . The DMCA requires that your notice of alleged copyright infringement include the following information: (1) description of the copyrighted work that is the subject of claimed infringement; (2) description of the alleged infringing content and information sufficient to permit us to locate the content; (3) contact information for you, including your address, telephone number and email address; (4) a statement by you that you have a good faith belief that the content in the manner complained of is not authorized by the copyright owner, or its agent, or by the operation of any law; (5) a statement by you, signed under penalty of perjury, that the information in the notification is accurate and that you have the authority to enforce the copyrights that are claimed to be infringed; and (6) a physical or electronic signature of the copyright owner or a person authorized to act on the copyright owner’s behalf. Failure to include all of the above information may result in the delay of the processing of your complaint.
['Ɛfa ho']
['BioMedLib de kɔmputa a wɔde di dwuma (mfidie a wɔde sua ade) na ɛma nsɛmmisa ne mmuae.']
['Yɛde nhoma ahorow a ɛfa nnuruyɛ mu ɔpepem 35 a ɛwɔ PubMed/Medline ne RefinedWeb mu na efii ase.']
